Dostarlimab as an Anticancer
INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 6 (6):
1937-1939 (Oktober 2022)Zusammenfassung
Dostarlimab JEMPERLI is a PD 1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient dMMR , recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum containing regimen. As determined by an FDA approved test this indication was granted rapid approval based on the rate of tumor response and the duration of the response. Continued approval for this indication is conditioned on further confirmatory trials demonstrating and documenting clinical benefit. In June 2022, the clinical trial NCT04165772 reported a 100 remission rate for rectal cancer. This clinical trial brought proof that we can match a tumor and the genetics of what is driving it, with therapy. This clinical trial continues to enroll patient and is currently enrolling patients with gastric, prostate, and pancreatic cancers. Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono and combination therapies. Tanuja Shaikh | Snehal Pawar | Mr. Arpit Rajaram Suralkar "Dostarlimab as an Anticancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-6 , October 2022, URL: https://www.ijtsrd.com/papers/ijtsrd52167.pdf Paper URL: https://www.ijtsrd.com/pharmacy/pharmacology-/52167/dostarlimab-as-an-anticancer/tanuja-shaikh